<ENAMEX TYPE="ORGANIZATION">ICN Biomedicals Inc.</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Flow General Inc.</ENAMEX> said they signed a definitive agreement for <ENAMEX TYPE="LOCATION">ICN</ENAMEX> to buy Flow's biomedical businesses for about $41 million.
<ENAMEX TYPE="ORGANIZATION">ICN</ENAMEX>, which also will assume $25 million of Flow debt, said it expects to benefit particularly from the Flow operation's overseas sales. <ENAMEX TYPE="ORGANIZATION">Flow</ENAMEX>'s biomedical operations include various reagents, drugs, and equipment for immunology, microbiology, and environmental work. The operations had revenue of about $100 million in the fiscal year ended June 30, 1989.
According to year-end results restated by <ENAMEX TYPE="ORGANIZATION">Flow General</ENAMEX>, the biomedical operations had a net loss of $16.6 million in the latest fiscal year, of which about $10 million represented nonrecurring charges and expenses. A spokesman for <ENAMEX TYPE="ORGANIZATION">ICN</ENAMEX>, a biotechnology concern based in <ENAMEX TYPE="LOCATION">Costa Mesa</ENAMEX>, <ENAMEX TYPE="LOCATION">Calif.</ENAMEX>, said the company expects to make the Flow operations profitable by efficiencies of scale and joint operation. <ENAMEX TYPE="ORGANIZATION">Flow</ENAMEX>, based in <ENAMEX TYPE="LOCATION">Mclean</ENAMEX>, <ENAMEX TYPE="LOCATION">Va.</ENAMEX>, has interests in defense work, electronics, and software.
